Ironwood Pharmaceuticals was downgraded to Hold following the resignation of its CFO, despite reporting record Linzess-driven revenues in Q1 2026. The company projects Linzess sales between $1.125 billion and $1.175 billion and total revenues of $450 million to $475 million for 2026. However, future challenges include Medicare price cuts in 2027 and generic competition expected in 2029. Ironwood is also advancing its pipeline with the launch of Apraglutide's Phase 3 trial in 2026, though competitive and regulatory risks may limit its $700 million peak sales potential. The company is improving its balance sheet and reducing debt but remains heavily reliant on Linzess with long development timelines for new products, limiting investor confidence.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
